Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03905421 · ClinicalTrials.gov registry record
Quality of Life Assessed With the PAH SYMPACT Questionnaire
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 390
- Enrollment target
NCT03905421: Completed study, sponsored by Mayo Clinic.
NCT03905421 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 390 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03905421 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 390 participants
- Enrollment target
Study Summary
Researchers are evaluating quality of life in pulmonary hypertension subjects using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire and assessing the questionnaires' performance with regard to relationship to other markers of disease severity, response to treatment, and outcome in a clinical practice setting.
Primary Outcome
Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2019-03-06 |
| Est. Completion | 2024-01-22 |
What the finished NCT03905421 record still lists
NCT03905421 is an observational study that tracks outcomes without assigning an intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03905421 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03905421 about?
NCT03905421 is a clinical study titled "Quality of Life Assessed With the PAH SYMPACT Questionnaire". Researchers are evaluating quality of life in pulmonary hypertension subjects using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire and assessing the questionnaires' performance with regard to relationship to other markers of disease severity, response to treatmen...
What is the current status of trial NCT03905421?
This trial is currently completed. The enrollment target is 390 participants. The study started on 2019-03-06. Estimated completion is 2024-01-22.
Who is sponsoring clinical trial NCT03905421?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI